<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03785067</url>
  </required_header>
  <id_info>
    <org_study_id>TRIDENT COG</org_study_id>
    <nct_id>NCT03785067</nct_id>
  </id_info>
  <brief_title>Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study</brief_title>
  <acronym>TRIDENT COG</acronym>
  <official_title>Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The George Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The George Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Sub-Study of an investigator initiated and conducted, multicentre, international,&#xD;
      double-blinded, placebo-controlled, parallel-group, randomised controlled trial (TRIDENT) to&#xD;
      determine the effect of more intensive long-term blood pressure control, provided by a fixed&#xD;
      low-dose combination blood pressure lowering pill (&quot;Triple Pill&quot;) strategy on top of standard&#xD;
      of care, for slowing memory decline as measured by Cambridge Neuropsychological Test&#xD;
      Automated Battery (CANTAB), in patients with a history of acute stroke due to intracerebral&#xD;
      haemorrhage (ICH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cognitive decline and dementia in ICH is high due to the common underlying vasculopathy of&#xD;
      cerebral small vessel disease (CSVD). However, in general, detailed cognitive outcomes in ICH&#xD;
      have been neglected, possibly due to the high mortality rate of ICH (up to 60% within the&#xD;
      first year).&#xD;
&#xD;
      Blood pressure (BP) management in those with ICH has been suboptimal. Most hypertensive&#xD;
      patients need more than two medications. Combination therapy may improve adherence and BP&#xD;
      reduction and reduce cardiovascular (CV) event rates. In the main TRIDENT study, it is&#xD;
      hypothesised that a fixed low-dose triple combination BP-lowering agent, termed the 'Triple&#xD;
      Pill' will prevent recurrent stroke. The Triple Pill is composed of a single capsule&#xD;
      containing either a combination of telmisartan 20 mg, amlodipine 2.5 mg and indapamide 1.25&#xD;
      mg, or placebo.&#xD;
&#xD;
      In addition to achieving optimal BP control, the Triple Pill also has the capacity to slow&#xD;
      cognitive decline and dementia in ICH survivors. Research shows that elevated BP is&#xD;
      associated with Alzheimer's disease and vascular dementia, even after accounting for prior&#xD;
      stroke or transient ischaemic attack, and large scale prospective studies have shown a 50%&#xD;
      reduction in dementia when BP is managed appropriately&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Contractual and financial issues.&#xD;
  </why_stopped>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Actual">February 3, 2021</completion_date>
  <primary_completion_date type="Actual">February 3, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Main Study: Multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial.&#xD;
Sub-Study: Multicentre, international, single-arm trial</intervention_model_description>
    <primary_purpose>Screening</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Main Study: Participants are double-blinded. Sub-Study: No blinding to neuropsychological assessments</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Memory as measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associates Learning (PAL) subtest</measure>
    <time_frame>Baseline, 18 and 36 months</time_frame>
    <description>Raw scores and z-scores will be used. Change scores on the CANTAB PAL will be computed between baseline, 18 and 36 months (primary endpoint).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change scores will be computed for CANTAB Rapid Visual Information Processing (RVP)</measure>
    <time_frame>Baseline, 18 and 36 months</time_frame>
    <description>Change scores will be computed for CANTAB RVP between baseline, 18 and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change scores will be computed for CANTAB Multi-tasking Test (MTT)</measure>
    <time_frame>Baseline, 18 and 36 months</time_frame>
    <description>Change scores will be computed for CANTAB MTT between baseline, 18 and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change scores will be computed for gold-standard neuropsychological assessments</measure>
    <time_frame>Baseline, 18 and 36 months</time_frame>
    <description>Change scores will be computed for gold-standard neuropsychological assessment between baseline, 18 and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnosis of all-cause dementia</measure>
    <time_frame>36 months</time_frame>
    <description>Diagnosis of all-cause dementia as determined by consensus of three blinded adjudicators based on established criteria following collection of data of the 3-year study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Cognitive Decline</condition>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Dementia, Vascular</condition>
  <condition>Cerebral Small Vessel Diseases</condition>
  <condition>Hypertension</condition>
  <condition>Stroke Hemorrhagic</condition>
  <arm_group>
    <arm_group_label>Triple Pill (Active Treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Main Study: Fixed low-dose combination BP-lowering pill (&quot;Triple Pill&quot;) telmisartan 20mg + amlodipine 2.5mg + indapamide 1.25mg&#xD;
Sub-Study: single-arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Main Study: Matched placebo, received via blinded study capsules&#xD;
Sub-Study: single-arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg</intervention_name>
    <description>1 capsule taken orally once daily for 36 months</description>
    <arm_group_label>Triple Pill (Active Treatment)</arm_group_label>
    <other_name>Triple Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>1 capsule taken orally once daily for 36 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eligible for, randomised and continuing in the TRIDENT Main Study&#xD;
&#xD;
          2. Must be able to attend the site conducting the cognitive assessments. In Sydney, this&#xD;
             will either be at the same site as where TRIDENT study is conducted or at the BMC,&#xD;
             University of Sydney, Camperdown.&#xD;
&#xD;
          3. Ability and willingness to undergo neuropsychological testing (i.e. have no major&#xD;
             visual, auditory or motor impairments)&#xD;
&#xD;
          4. Language spoken compatible with CANTAB administration (i.e. CANTAB will be&#xD;
             administered in the local language(s) of the country in question. E.g. in Australia,&#xD;
             the CANTAB will only be administered in English).&#xD;
&#xD;
          5. Provision of written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Study medication has been permanently stopped prior to or at the 6-month visit of the&#xD;
             TRIDENT main study&#xD;
&#xD;
          2. Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) score of 3.313&#xD;
             or higher&#xD;
&#xD;
          3. Cognitive performance indicative of dementia at 6-month TRIDENT main study visit&#xD;
             defined by Montreal Cognitive Assessment (MoCA) score less than 2414.&#xD;
&#xD;
          4. Evidence of rapid deterioration suggestive of dementia by decline of 3 points in MoCA&#xD;
             assessments between randomisation and the 6-month study visit in the TRIDENT main&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Craig Anderson</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof Sharon Naismith</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sydney</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TRIDENT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Cerebral Small Vessel Diseases</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Hemorrhagic Stroke</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Indapamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

